MIDLAND, Texas, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback” or the “Company”) today announced financial and operating results for the fourth quarter and ...
MIDLAND, Texas, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Viper Energy, Inc., (NASDAQ:VNOM) (“Viper” or the “Company”), a subsidiary of Diamondback Energy, Inc. (NASDAQ:FANG) (“Diamondback”), today announced ...
Venturi Wealth Management LLC decreased its position in Diamondback Energy, Inc. (NASDAQ:FANG – Free Report) by 30.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Diamondback Energy shares are trading higher on Tuesday after the company reported better-than-expected 2024 fiscal-year ...
Diamondback Energy Inc. is in talks to form a power joint venture that would solve some of the shale giant’s own needs in the ...
Mizuho raised the firm’s price target on Diamondback Energy (FANG) to $204 from $201 and keeps an Outperform rating on the shares following the ...
Diamondback Energy reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the quarter.
As the war in Ukraine enters its third year, the House of Ukraine in Balboa Park continues its relentless efforts to support those affected by the conflict. A new planet discovered? The Hubble Space ...
13h
Stocktwits on MSNDiamondback Energy Rises Aftermarket On Q4 Profit Beat, Retail’s ElatedDiamondback Energy (FANG) stock gained in extended trading on Monday after the company’s fourth-quarter earnings topped Wall ...
Diamondback Energy (FANG) reported $3.71 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 66.6%. EPS of $3.64 for the same period compares to $4.74 a ...
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara's lead program, ficerafusp alfa, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results